Neuronetics (NASDAQ:STIM) Rating Increased to Hold at Wall Street Zen

Neuronetics (NASDAQ:STIM) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Neuronetics currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Neuronetics Stock Down 6.9%

Neuronetics stock opened at $1.35 on Friday. Neuronetics has a fifty-two week low of $1.00 and a fifty-two week high of $5.92. The stock has a market cap of $92.46 million, a PE ratio of -1.65 and a beta of 0.71. The firm’s 50-day simple moving average is $2.32 and its 200 day simple moving average is $3.17. The company has a debt-to-equity ratio of 2.09, a quick ratio of 2.09 and a current ratio of 2.24.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Neuronetics had a negative net margin of 33.88% and a negative return on equity of 131.15%. The firm had revenue of $37.30 million during the quarter, compared to analysts’ expectations of $37.85 million. Research analysts predict that Neuronetics will post -1.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Neuronetics

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG increased its position in Neuronetics by 580.7% in the third quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock worth $5,910,000 after buying an additional 1,846,801 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Neuronetics by 2,993.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock worth $2,320,000 after acquiring an additional 610,014 shares during the period. Geode Capital Management LLC increased its holdings in Neuronetics by 172.3% in the 2nd quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock worth $3,068,000 after acquiring an additional 556,268 shares during the last quarter. Wexford Capital LP increased its holdings in Neuronetics by 83.1% in the 3rd quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock worth $3,214,000 after acquiring an additional 534,155 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in Neuronetics by 260.7% in the 3rd quarter. HighTower Advisors LLC now owns 577,069 shares of the company’s stock valued at $1,575,000 after acquiring an additional 417,087 shares during the period. 53.59% of the stock is owned by institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.